Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
Daiichi Sankyo
Fish and Richardson
Accenture
Merck
Harvard Business School
Johnson and Johnson
US Army
Deloitte

Generated: December 11, 2017

DrugPatentWatch Database Preview

SIVEXTRO Drug Profile

« Back to Dashboard

Which patents cover Sivextro, and what generic alternatives are available?

Sivextro is a drug marketed by Cubist Pharms Llc and is included in two NDAs. There are three patents protecting this drug.

This drug has seventy-one patent family members in thirty-seven countries and thirteen supplementary protection certificates in nine countries.

The generic ingredient in SIVEXTRO is tedizolid phosphate. One supplier is listed for this compound. Additional details are available on the tedizolid phosphate profile page.

Summary for SIVEXTRO

Drug patent expirations by year for SIVEXTRO

Pharmacology for SIVEXTRO

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms LlcSIVEXTROtedizolid phosphatePOWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphateTABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphatePOWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphateTABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphatePOWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphatePOWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphateTABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphatePOWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphateTABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphateTABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SIVEXTRO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,163,043Oxazolidinone derivatives► Subscribe
9,624,250Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- -hydroxymethyl oxazolidin-2-one dihydrogen phosphate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SIVEXTRO

Country Document Number Estimated Expiration
European Patent Office2305657► Subscribe
Morocco33092► Subscribe
Costa Rica20110464► Subscribe
South Korea20110120311► Subscribe
Tunisia2011000381► Subscribe
China102516238► Subscribe
Ukraine114068► Subscribe
World Intellectual Property Organization (WIPO)2005058886► Subscribe
New Zealand712289► Subscribe
Japan5584705► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SIVEXTRO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00759Netherlands► SubscribePRODUCT NAME: TEDIZOLID, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/15/991 20150323
2015000078Germany► SubscribePRODUCT NAME: TEDIZOLID, GEGEBENENFALLS IN FORM EINES ESTERS, INSBESONDERE EINES PHOSPHATS, ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/991/001-003 20150323
15/048Ireland► SubscribePRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/991 20150323
0762Netherlands► SubscribePRODUCT NAME: TEDIZOLID, DESGEWENST IN DE VORM VAN EEN ESTER, IN HET BIJZONDER EEN FOSFAAT, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/15/991 20150323
2015032,C1699784Lithuania► SubscribePRODUCT NAME: TEDIZOLIDAS, PASIRINKTINAI ESTERIO PAVIDALU, YPAC FOSFATO ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/991 20150323
2015 00048Denmark► SubscribePRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TEDIZOLID PHOSPHATE; REG. NO/DATE: EU/1/15/991 20150325
90047-5Sweden► SubscribePRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/991 20150325
834Luxembourg► SubscribePRODUCT NAME: TEDIZOLIDE, OPTIONNELLEMENT SOUS LA FORME D UN ESTER, EN PARTICULIER UN PHOSPHATE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150325
0759Netherlands► SubscribePRODUCT NAME: TEDIZOLID, DESGEWENST IN DE VORM VAN EEN ESTER, IN HET BIJZONDER EEN FOSFAAT, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/15/991 20150323
C0062France► SubscribePRODUCT NAME: TEDIZOLIDE,EVENTUELLEMENT SOUS LA FORME D'UN ESTER ,EN PARTICULIER UN PHOSPHATE,OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/991 20150325
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Dow
Baxter
Cantor Fitzgerald
Chubb
AstraZeneca
US Army
Federal Trade Commission
Colorcon
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot